National Cancer Center, Korea: Not applicable (device, behavioral) study in Advanced Solid Tumors, Metastatic Solid Tumors (2800 participants)
National Cancer Center, Korea: Not applicable (device, behavioral) study in Advanced Solid Tumors, Metastatic Solid Tumors (2800 participants). Its enrollment of 2,800 is top-decile (97th percentile of 8,879 records). Dated 13 days ago, it is in the active follow-up window. Score 55/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 2,800 · 97th percentile of 8,879 ClinicalTrialStartPulse records · 35.0x the median
Free preview: all 14 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | National Cancer Center, Korea |
| Sponsor type | Non-US government |
| Study | Master Protocol for Basket Clinical Trials of Targeted Therapies Based on Proteome and Whole Exome Sequencing Screening in Patients With Advanced Solid Tumors |
| NCT ID | NCT07891169 |
| Phase | Not applicable (device, behavioral) |
| Status | active not recruiting |
| Conditions | Advanced Solid Tumors; Metastatic Solid Tumors; Locally Advanced Solid Tumors; Recurrent Solid Tumors; Proteogenomic Screening and Molecular Signaling; Basket Clinical Trial Framework |
| Intervention types | drug |
| Target enrollment | 2800 |
| Site countries | South Korea |
| Posted | 2026-10-23 |
| Planned start | 2024-11-18 |
| Event | Newly registered study |
| Event date | 2026-10-23 |
| enrollment percentile | 97th of 8,879 (median 80, 35.0x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch National Cancer Center, Korea
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Free first: a 10-record sample of records
See the real columns before you buy. One confirmation email, nothing else unless you opt in.
Unlock National Cancer Center, Korea + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-23
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: National Cancer Center, Korea and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- National Cancer Center, Korea's enrollment: 97th percentile of 8,879 records
- Timing: Medium: dated in the last 30 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
55 / 100 Score
- Posted in the last two weeks.
- 2800 participants planned.
What is the ClinicalTrialStartPulse record for National Cancer Center, Korea?
National Cancer Center, Korea registered a Not applicable (device, behavioral) study (NCT07891169) in Advanced Solid Tumors targeting 2800 participants, posted 2026-10-23.
How does National Cancer Center, Korea compare to other ClinicalTrialStartPulse records?
This is a top-decile record: its enrollment of 2,800 is 35.0x the median of 80 across 8,879 records. It is fresh: dated 13 days ago, inside the window where early outreach matters most.
National Cancer Center, Korea vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| National Cancer Center, Korea | NONUS | 2,800 | 97th | 2026-10-23 |
| Galderma R&D | NONUS | 326 | 84th | 2026-11-02 |
| Galderma R&D | NONUS | 162 | 72nd | 2026-11-03 |
| A.M.I. Agency for Medical Innovations GmbH | NONUS | 100 | 60th | 2026-10-30 |
Related records
ClinicalTrialStartPulse: Not applicable (device, behavioral) ClinicalTrialStartPulse: Outside the US only
How to monitor National Cancer Center, Korea and peer not applicable (device, behavioral) records
Get new ClinicalTrialStartPulse records like National Cancer Center, Korea by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.